ReleaseWire

Global Markets Direct's, 'Opexa Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Opexa Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'MaxCyte, Inc. - Product Pipeline Review - 2014', provides an overview of the MaxCyte, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Amarna Therapeutics B.V. - Product Pipeline Review - 2014', provides an overview of the Amarna Therapeutics B.V.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Hisamitsu Pharmaceutical Co., Inc. - Product Pipeline Review - 2014', provides an overview of the Hisamitsu Pharmaceutical Co., Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Retinopathy - Pipeline Review, H2 2014', provides an overview of the Retinopathy's therapeutic pipeline.

GlobalData's clinical trial report, "Influenza A and B Infections Global Clinical Trials Review, H2, 2014" provides data on the Influenza A and B Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Influenza A and B Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Influenza A and B Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Phosphagenics Limited - Product Pipeline Review - 2014', provides an overview of the Phosphagenics Limited's pharmaceutical research and development focus.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Nintedanib (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

GlobalData's clinical trial report, "Bronchiolitis Obliterans Global Clinical Trials Review, H2, 2014" provides data on the Bronchiolitis Obliterans clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bronchiolitis Obliterans. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bronchiolitis Obliterans. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'PhaseRx, Inc. - Product Pipeline Review - 2014', provides an overview of the PhaseRx, Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Apnea Global Clinical Trials Review, H2, 2014" provides data on the Apnea clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Apnea. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Apnea. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Food Allergy - Pipeline Review, H2 2014', provides an overview of the Food Allergy's therapeutic pipeline.

Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.

Global Markets Direct's, 'Ferring International Center S.A. - Product Pipeline Review - 2014', provides an overview of the Ferring International Center S.A.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Protein Sciences Corporation - Product Pipeline Review - 2014', provides an overview of the Protein Sciences Corporation's pharmaceutical research and development focus.

Needle-free drug delivery technologies are used to deliver drugs or vaccines into a patient's body without the need for a traditional needle. The primary objectives of the development of these technologies are to eliminate NSI and its associated complications and increase patient compliance and comfort. Needle-free drug delivery systems include jet injectors, microneedles, nanopatches, and vaccine implants. The advantages of these systems over conventional syringes are expanded immunization coverage, decreased healthcare costs, and increased patient compliance. Needle-free systems expand the range of molecules that can be delivered transdermally with improved efficiency and enhance the efficacy of the drug or vaccine. Microneedles increase the efficacy of vaccines by targeting them to antigen-presenting cells mainly found just beneath the stratum corneum of the skin.

Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country.

GlobalData's clinical trial report, "Empyema Global Clinical Trials Review, H2, 2014" provides data on the Empyema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Empyema. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Empyema. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

CEL-SCI Corporation announced that during November it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). Patient screening has begun at new clinical centers in France, Turkey, Poland, Sri Lanka, Russia and Taiwan.

Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Christine Silverstein as director of investor relations, effective immediately. She will report to Michael Becker, senior vice president of finance and corporate development at Relmada.

Getting the right fertility medication from a trusted source is extremely important for anyone undertaking the treatment. The Pharmacists at Rox San are certified professionals with over 20 years experience working with doctors and advising patients. The range of medication in stock is extensive, and the pharmacy also provides a 24-hour phone support service for customers.

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCQB:INNV) announced today it has expanded its exclusive marketing and distribution agreement with Tramorgan Limited ("Tramorgan") ,and granted to Tramorgan additional rights to market and sell Innovus Pharma's oral dietary supplement to promote sexual and cognitive health, Vesele® in the United Kingdom ("UK"). Under the agreement, Innovus is eligible to receive up to $13 million dollars in sales milestone payments plus fifty percent (50%) royalties based on Tramorgan's sales of Vesele® in the UK.

Hormone replacement therapy is used by both men and women in order to supplement the amount of hormone produced naturally by the body. As people age, the hormone balance changes and can have a range of effects that are sometimes undesirable. Hormone replacement therapy is the perfect way to mitigate these effects and maintain overall quality of life. Rox San Pharmacy as a professional compounding pharmacy is able to offer customized hormone therapy that provides the particular dosage form and strength on an individual basis.

Find out which medications work BEST BEFORE they're taken!

Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H2 2014', provides an overview of the Acute Lung Injury's therapeutic pipeline.